Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked higher than
99% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. PRTA: No Debt )
PRTA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.95
PRTA's Equity to Asset is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PRTA: 0.95 )
PRTA' s 10-Year Equity to Asset Range
Min: -1.78   Max: 0.98
Current: 0.95

-1.78
0.98
Interest Coverage No Debt
PRTA's Interest Coverage is ranked higher than
99% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRTA: No Debt )
PRTA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 45.68
M-Score: 63.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13.07
PRTA's Operating margin (%) is ranked higher than
81% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. PRTA: -13.07 )
PRTA' s 10-Year Operating margin (%) Range
Min: -5980.33   Max: -13.07
Current: -13.07

-5980.33
-13.07
Net-margin (%) -14.06
PRTA's Net-margin (%) is ranked higher than
80% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. PRTA: -14.06 )
PRTA' s 10-Year Net-margin (%) Range
Min: -6064.5   Max: -14.06
Current: -14.06

-6064.5
-14.06
ROE (%) -2.85
PRTA's ROE (%) is ranked higher than
84% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. PRTA: -2.85 )
PRTA' s 10-Year ROE (%) Range
Min: -68.99   Max: -3.09
Current: -2.85

-68.99
-3.09
ROA (%) -2.72
PRTA's ROA (%) is ranked higher than
85% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. PRTA: -2.72 )
PRTA' s 10-Year ROA (%) Range
Min: -1640.13   Max: -2.94
Current: -2.72

-1640.13
-2.94
ROC (Joel Greenblatt) (%) -203.36
PRTA's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. PRTA: -203.36 )
PRTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2303.58   Max: -204.81
Current: -203.36

-2303.58
-204.81
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PRTA Guru Trades in Q1 2014

Vanguard Health Care Fund 1,327,524 sh (+47.09%)
Jim Simons 79,112 sh (+22.46%)
» More
Q2 2014

PRTA Guru Trades in Q2 2014

Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 30,549 sh (New)
Vanguard Health Care Fund 1,662,794 sh (+25.26%)
Jim Simons 51,900 sh (-34.40%)
» More
Q3 2014

PRTA Guru Trades in Q3 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Paul Tudor Jones Sold Out
Leon Cooperman 80,000 sh (-20.00%)
Jim Simons 17,300 sh (-66.67%)
» More
Q4 2014

PRTA Guru Trades in Q4 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Leon Cooperman Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.90
PRTA's P/B is ranked higher than
85% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. PRTA: 3.90 )
PRTA' s 10-Year P/B Range
Min: 0.84   Max: 5.16
Current: 3.9

0.84
5.16
P/S 18.36
PRTA's P/S is ranked higher than
68% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. PRTA: 18.36 )
PRTA' s 10-Year P/S Range
Min: 8.29   Max: 900.25
Current: 18.36

8.29
900.25
PFCF 296.80
PRTA's PFCF is ranked higher than
88% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: 296.80 )
PRTA' s 10-Year PFCF Range
Min: 139.62   Max: 308.6
Current: 296.8

139.62
308.6
POCF 276.14
PRTA's POCF is ranked higher than
88% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: 276.14 )
PRTA' s 10-Year POCF Range
Min: 129.64   Max: 2363
Current: 276.14

129.64
2363
EV-to-EBIT -115.16
PRTA's EV-to-EBIT is ranked higher than
50% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: -115.16 )
PRTA' s 10-Year EV-to-EBIT Range
Min: -348.9   Max: 0.9
Current: -115.16

-348.9
0.9
Current Ratio 24.86
PRTA's Current Ratio is ranked higher than
97% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PRTA: 24.86 )
PRTA' s 10-Year Current Ratio Range
Min: 0.01   Max: 72.16
Current: 24.86

0.01
72.16
Quick Ratio 24.86
PRTA's Quick Ratio is ranked higher than
97% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. PRTA: 24.86 )
PRTA' s 10-Year Quick Ratio Range
Min: 0.01   Max: 72.16
Current: 24.86

0.01
72.16
Days Sales Outstanding 12.41
PRTA's Days Sales Outstanding is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. PRTA: 12.41 )
PRTA' s 10-Year Days Sales Outstanding Range
Min: 12.41   Max: 31.32
Current: 12.41

12.41
31.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
PRTA's Price/Net Cash is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. PRTA: 3.70 )
PRTA' s 10-Year Price/Net Cash Range
Min: 1.06   Max: 3.46
Current: 3.7

1.06
3.46
Price/Net Current Asset Value 3.70
PRTA's Price/Net Current Asset Value is ranked higher than
95% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. PRTA: 3.70 )
PRTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.05   Max: 3.43
Current: 3.7

1.05
3.43
Price/Tangible Book 3.60
PRTA's Price/Tangible Book is ranked higher than
91% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. PRTA: 3.60 )
PRTA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 4.35
Current: 3.6

1
4.35
Price/Median PS Value 0.50
PRTA's Price/Median PS Value is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PRTA: 0.50 )
PRTA' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 20.09
Current: 0.5

0.29
20.09
Earnings Yield (Greenblatt) -0.90
PRTA's Earnings Yield (Greenblatt) is ranked higher than
82% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. PRTA: -0.90 )
PRTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.9   Max: 74709.2
Current: -0.9

-0.9
74709.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PT.Germany,
Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 


More From Other Websites
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
PROTHENA CORP PLC Files SEC form 8-K, Regulation FD Disclosure Mar 23 2015
CEO: My $26 stock going to $200 Mar 20 2015
Prothena shares jump on Parkinson's drug study data Mar 20 2015
Prothena soars on study results for Parkinson's disease drug Mar 20 2015
How Large Is Prothena’s Market Opportunity? Mar 20 2015
Prothena Soars On Parkinson's Drug; Biogen In Focus Mar 19 2015
Prothena Reports Positive Results for Parkinson's Treatment Mar 19 2015
Nike shares rise after profit beat, revenue miss Mar 19 2015
SeaWorld, Mattress Firm Lead Thursday's After-Hours Movers Mar 19 2015
PROTHENA CORP PLC Files SEC form 8-K, Other Events Mar 19 2015
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of... Mar 19 2015
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of... Mar 19 2015
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of... Mar 19 2015
PROTHENA CORP PLC Financials Mar 19 2015
PROTHENA CORP PLC Files SEC form 10-K, Annual Report Mar 13 2015
Prothena reports 4Q loss Mar 05 2015
Prothena reports 4Q loss Mar 05 2015
PROTHENA CORP PLC Files SEC form 8-K, Results of Operations and Financial Condition Mar 05 2015
Prothena Corporation PLC Earnings Call scheduled for 4:30 pm ET today Mar 05 2015
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial... Mar 05 2015
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial... Mar 05 2015
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial... Mar 05 2015
Q4 2014 Prothena Corporation PLC Earnings Release - After Market Close Mar 05 2015
Prothena to Present at the 2015 RBC Capital Markets' Healthcare Conference in New York on February... Feb 18 2015
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of... Dec 16 2014
BUZZ-U.S. Stocks on the Move-Talisman Energy, Boeing, Healthcare Trust, Russian ADRs Dec 16 2014
Global renal biomarkers market player Prothena sees initial success with NEOD001 drug Dec 14 2014
HTML PDF Dec 10 2014
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York Dec 08 2014
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing... Dec 02 2014
Prothena posts 3Q loss Nov 03 2014
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress Nov 03 2014
BUZZ-U.S. Stocks on the Move-Schlumberger, Sequential, Broadcaster stocks Jun 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK